VOTRIENT 400 MG 60 TB

VOTRIENT (Pazopanib) is an oral medication used in the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. VOTRIENT is a tyrosine kinase inhibitor (TKI) that interferes with the growth and spread of cancer cells by targeting specific proteins responsible for tumor growth and angiogenesis. It is a vital option in oncology due to its targeted mechanism, providing an effective treatment for specific cancers.

How VOTRIENT Works

Mechanism of Action

1. Tyrosine Kinase Inhibition:
   • VOTRIENT works by inhibiting tyrosine kinases, enzymes that play a critical role in cell signaling and are essential for cell division and survival. It specifically targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and other proteins involved in cancer growth.
2. Blocking Angiogenesis:
   • By inhibiting VEGFR, VOTRIENT disrupts angiogenesis, the process through which tumors form new blood vessels to sustain their growth. This starves the cancer cells of oxygen and nutrients, leading to slower tumor growth.
3. Suppression of Tumor Cell Proliferation:
   • The inhibition of PDGFR and other related receptors also impedes the proliferation of tumor cells directly, reducing the overall growth rate of the cancer.
4. Targeted Cancer Therapy:
   • VOTRIENT’s targeted action minimizes damage to normal, healthy cells, making it a focused treatment that specifically hinders cancer cell survival and replication.

Side Effects

Common Side Effects

• Fatigue:
  • General tiredness or lack of energy is frequently reported among patients taking VOTRIENT.
• Diarrhea:
  • Gastrointestinal disturbances are common and may be managed with supportive care.
• Hypertension (High Blood Pressure):
  • Elevated blood pressure is a manageable side effect but requires monitoring during treatment.
• Nausea and Vomiting:
  • These symptoms are common but can often be controlled with anti-nausea medications.
• Loss of Appetite:
  • Anorexia or reduced appetite can occur, sometimes leading to weight loss.
• Hair Color Changes:
  • Lightening or graying of hair has been observed in some patients.
• Rash and Skin Changes:
  • Skin reactions such as rash, dryness, and discoloration are relatively common.
• Abnormal Liver Function Tests:
  • Elevated liver enzymes indicate possible liver stress, requiring regular monitoring.

Serious Side Effects

• Liver Toxicity:
  • VOTRIENT can cause serious liver damage, including fatal hepatotoxicity. Liver function tests must be performed before and during treatment.
• Cardiac Dysfunction:
  • Risk of heart problems, including heart failure and QT prolongation, necessitating cardiovascular monitoring.
• Gastrointestinal Perforations and Fistula:
  • Serious gastrointestinal complications may occur, requiring immediate medical attention.
• Thrombotic Microangiopathy (TMA):
  • A rare but serious condition involving small blood vessel damage, which can affect the kidneys and other organs.
• Hemorrhage:
  • There is an increased risk of serious bleeding, including gastrointestinal and intracranial hemorrhages.
• Pneumonitis:
  • Inflammation of lung tissue, which can be severe and requires discontinuation of the drug.

Indications

VOTRIENT is indicated for:

• Advanced Renal Cell Carcinoma (RCC):
  • Used as a first-line or subsequent therapy for patients with metastatic RCC.
• Advanced Soft Tissue Sarcoma (STS):
  • Indicated for patients with advanced soft tissue sarcoma who have previously received chemotherapy.

Contraindications

VOTRIENT should not be used in the following conditions:

• Severe Hepatic Impairment:
  • Contraindicated in patients with severe liver dysfunction due to the high risk of hepatotoxicity.
• Uncontrolled Hypertension:
  • Patients with poorly controlled high blood pressure should not take VOTRIENT.
• Recent Hemorrhage or Significant Bleeding Risk:
  • Those with recent bleeding events or high risk for hemorrhage should avoid VOTRIENT.
• Pregnancy:
  • VOTRIENT can cause fetal harm and is contraindicated in pregnant women. Effective contraception must be used during treatment.
• Allergic Reaction to Pazopanib:
  • Patients with known hypersensitivity to pazopanib or any component of the formulation should not take this medication.

Price in Different Countries

The price of VOTRIENT 400 mg 60 tablets varies significantly by country, depending on factors such as healthcare systems, insurance coverage, and market regulations. Below is a table showing the approximate price in different countries.

Country	Price (Per 60 Tablets)	Reference
United States	$8,000 – $9,500	GoodRx
United Kingdom	£6,000 – £7,500	NHS UK
Canada	CAD $10,000 – $11,500	Canada Drugs
Australia	AUD $11,000 – $12,500	PBS Australia
India	₹550,000 – ₹650,000	1mg

Top 5 Global Brands

1. VOTRIENT (Pazopanib) – Novartis:
   • The original brand manufactured by Novartis, widely available across major global markets for the treatment of RCC and STS.
2. Natco Pazopanib – Natco Pharma:
   • A generic alternative available in India, offering a cost-effective option for patients requiring treatment.
3. Mylan Pazopanib – Mylan:
   • Provides a generic version in the United States and Europe, expanding access to this critical therapy.
4. Teva Pazopanib – Teva Pharmaceuticals:
   • Available in various European countries, Teva’s generic version is a trusted alternative for healthcare providers.
5. Cipla Pazopanib – Cipla Ltd.:
   • Known for affordable oncology drugs, Cipla’s version is available in several Asian and African markets.